06996.HK
Antengene Corporation Limited
HKSE · Healthcare · Biotechnology · CN
HKD 2.83
−0.53%Year over year
Reported trailing growth
- Revenue
- +561.7%
- EBITDA
- +166.2%
- EBIT
- +154.8%
- EPS
- +122.2%
- Free cash flow
- +55.5%
- Operating cash flow
- +69.6%
Forward estimates
Based on analyst estimates
- Revenue
- -42.1%
- EBITDA
- +2.6%
- EPS
- +141.8%
Three-year CAGR
- Revenue
- -13.0%
- EBITDA
- +36.4%
- EBIT
- +34.5%
- Net income
- +25.1%
- EPS
- +25.5%
- Free cash flow
- +53.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026